|
Mild cognitive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
Subgroup analysis showed that the plasma CLU concentration was significantly increased only in the AD group (SDM = 1.85, 95% CI 0.84-2.85, P < 0.001), but not in MCI or other dementias.
|
30291488 |
2019 |
|
Mild cognitive disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The frequency of the C allele of CLU rs11136000 was significantly different between cases and controls and was associated with MCI risk (OR 1.79, P = 0.019).
|
30560405 |
2019 |
|
Mild cognitive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our results showed a reduction in the total antioxidant capacity (TAC) and an increase of the stress-response proteins apolipoprotein J (ApoJ) and Klotho in MCI subjects.
|
30445127 |
2019 |
|
Mild cognitive disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To evaluate cognitive performance and presence of polymorphisms of the genes SORL1(rs11218304), PVRL2(rs6859), CR1(rs6656401), TOMM40(rs2075650), APOE (isoforms ɛ2, ɛ3, ɛ4), PICALM(rs3851179), GWAS_14q(rs11622883), BIN1(rs744373), and CLU (rs227959 and rs11136000) in patients with MCI and healthy individuals.
|
30503753 |
2018 |
|
Mild cognitive disorder
|
0.400 |
Biomarker
|
disease |
CTD_human |
To evaluate cognitive performance and presence of polymorphisms of the genes SORL1(rs11218304), PVRL2(rs6859), CR1(rs6656401), TOMM40(rs2075650), APOE (isoforms ɛ2, ɛ3, ɛ4), PICALM(rs3851179), GWAS_14q(rs11622883), BIN1(rs744373), and CLU (rs227959 and rs11136000) in patients with MCI and healthy individuals.
|
30503753 |
2018 |
|
Mild cognitive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
We conclude that SNPs in CLU are potential markers for MCI to AD progression.
|
26976043 |
2017 |
|
Mild cognitive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
In MCI syndrome, APOE is confirmed as a pheno-conversion factor leading from MCI to AD, and clusterin is a promising candidate.
|
27237222 |
2016 |
|
Mild cognitive disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Effect of CLU genetic variants on cerebrospinal fluid and neuroimaging markers in healthy, mild cognitive impairment and Alzheimer's disease cohorts.
|
27229352 |
2016 |
|
Mild cognitive disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
CLU-rs11136000-G associated with worse baseline memory and incident MCI/LOAD.
|
25189118 |
2015 |
|
Mild cognitive disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We screened 37 AD, 8 mild cognitive impairment (MCI), 3 AD and CVD (cerebrovascular disease), 3 MCI and CVD, 8 frontotemporal dementia (FTD) and 2 progressive supranuclear palsy (PSP) patients, and 28 normal controls (NCs).We sequenced PSEN1, PSEN2 and APP (EOAD risk factors), as well as MAPT, GRN and TARDBP for all cases and NCs, and analysed the APOE, CLU, CR1 and PICALM genotypes as well as the MAPT and ACE haplotypes (LOAD risk factors) for the AD (n = 37) and AD + MCI (n = 45) cases and NCs (n = 28).We identified variants in PSEN1, PSEN2 and TARDBP across a range of phenotypes (AD, AD and CVD, FTD and PSP), suggesting that screening of all known candidate genes of Alzheimer's and non-Alzheimer's forms of dementias in all dementia cases might be warranted.
|
26159191 |
2015 |
|
Mild cognitive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
We used a task of executive attention during fMRI in participants genotyped for two Alzheimer's risk alleles: APOE-ε4 and CLU-C. Executive attention is a sensitive indicator of the progression of Alzheimer's even in the early stages of mild cognitive impairment, but has not yet been investigated as a marker of Alzheimer's risk in young adults.
|
24388797 |
2014 |
|
Mild cognitive disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Plasma clusterin was not influenced by genotype in the MCI and AD subjects, although in control subjects plasma clusterin was lower in the TT vs. TC genotypes (157.6 ± 53.4 vs. 188.6 ± 30.5 μg/ml; p<0.05).
|
24117116 |
2013 |